3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential

Three mid-cap ideas for patient, risk-tolerant investors: CRISPR Therapeutics (market cap ~ $5.2bn) owns an approved one-time gene therapy, Casgevy, for sickle cell disease and beta thalassemia but rollout has been slow (roughly 300 patients referred) and the company has posted sizeable losses (~$451m over the past nine months), implying upside depends on scaling adoption. Viking Therapeutics (~$4.3bn) is a higher-risk play with no revenue yet; its GLP‑1 candidate VK2735 has entered phase 3 after prior data showing up to 14.7% weight loss at 13 weeks, offering potential for multibillion-dollar sales or M&A exposure if approved amid a market Goldman Sachs pegs as large as ~$95bn by 2030, but Viking reported ~ $237m of losses TTM. e.l.f. Beauty combines strong youth brand traction (36% teen mindshare in Piper Sandler data) and a $1bn acquisition of Rhode with projected 2025 revenue around $1.6bn and adjusted net income of at least $165m, yet shares are down >40% YTD due to tariff risk (≈80% production in China); pricing actions could blunt headwinds and a US‑China tariff resolution would be a catalyst.

Analysis

CRISPR Therapeutics (market cap ~ $5.2bn) owns an approved one-time gene therapy, Casgevy, for sickle cell disease and transfusion-dependent beta thalassemia that can command prices above $2 million; commercial rollout has been slow with roughly 300 patients referred to treatment centers nearly two years after first approval, and the company reported net losses of ~$451m over the past nine months. Slow adoption and continued cash burn are the primary constraints on valuation despite the durable clinical value of a one-time curative therapy.

Viking Therapeutics (~ $4.3bn) is a pure development-stage play with no revenue; its GLP-1 candidate VK2735 has entered phase 3 after prior data showing up to 14.7% body-weight reduction at 13 weeks and an oral program earlier in development. The company recorded >$237m of losses over the trailing 12 months, so upside depends entirely on phase-3 efficacy/safety, regulatory success, or strategic M&A given the Goldman Sachs estimate of a ~$95bn GLP-1 market by 2030.

e.l.f. Beauty combines strong youth brand momentum (36% teen mindshare in Piper Sandler data) and a $1bn acquisition of Rhode with projected revenue ~ $1.6bn and adjusted net income of at least $165m this year, but shares are down >40% YTD due to tariff exposure (≈80% production in China). The company has raised prices by $1 to offset headwinds; a negotiated U.S.–China tariff resolution or demonstrable margin recovery would be a clear positive catalyst.

Key Decisions for Investors

• For CRSP, consider a patient, long-term core position sized to your risk tolerance but monitor commercial KPIs (monthly referrals, treatment starts, reimbursement and net revenue) and quarterly cash burn; add only if referrals and revenue acceleration are evident
• For VKTX, treat as a high-risk, event-driven speculative position: limit sizing, wait for pivotal phase‑3 topline and safety data before materially increasing exposure, and watch for partnership or takeover interest as potential upside catalysts
• For ELF, consider buying selectively on further weakness if your investment thesis hinges on tariff resolution and durable youth demand; prioritize exposure after signs of margin stabilization or clearer trade-policy progress given the >40% YTD decline
• Across the three names, size positions to reflect binary outcomes (smallest for VKTX), maintain liquidity to add on de-risking events, and monitor company-reported commercial metrics and U.S.–China trade developments closely